Giorgia Battipaglia, MD, Federico II University of Naples, Naples, Italy, talks on the use of anti-thymocyte globulin (ATG) versus post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GvHD) prophylaxis in patients undergoing matched unrelated donor (MUD) and one-antigen mismatched unrelated donor (MMUD) transplantation. Whilst a recent study did not show any significant differences in outcomes in patients treated with PTCy or ATG in the MUD setting, a recent retrospective study from the EBMT showed that PTCy resulted in better patient outcomes after one-antigen MMUD, and significantly reduced the incidence of grade 2-4 GvHD compared to patients treated with ATG. Although studies with smaller cohorts have reported similar results, further prospective data is needed to confirm these findings. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
